Background: Although serological screening tests for blood-borne hepatitis viruses have effectively reduced the risk of HBV transmission through transfusion of infected blood, there is still a possibility that infected blood units from occult carriers being released into the blood supply. The aim of this study was to determine the prevalence of anti-HBc among Iranian blood donors and evaluate the presence of HBV DNA in HBsAg negative plasma samples.
Methods: In the present study, 5000 HBsAg negative samples were collected from donors in blood transfusion centers in Tehran. All HBsAg negative samples were tested for the presence of anti-HBc antibody and anti-HBs antibody (HBsAb) using ELISA method. Also, all HBsAg negative samples were tested for the presence of HBV DNA by real-time PCR.
Results: Four hundred ninety nine (9.98%) out of the 5000 HBsAg negative blood donors were anti-HBc positive. Out of 499 anti-HBc positive samples that were tested for anti-HBs, 394 (78.4 %) were anti-HBs positive, and 275 (62.7%) had an antibody titer greater than 100 IU/mL. HBV DNA was detected in two samples.
Conclusion: In countries with intermediate rate of HBV infection like Iran, the prevalence of anti-HBc antibody in HBsAg negative blood donors is found to be high. As a result, routine anti-HBc screening of HBsAg-negative blood donors without complementary tests (anti-HBs / HBV-DNA) can limit the number of blood transfusions. Therefore, it might be better to include the detection of HBV DNA along with the routine tests.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Objective: To analyze the clinical effectiveness of Entecavir (ETV) and Tenofovir Disoproxil Fumarate (TDF) Tablets for the treatment of chronic hepatitis B (CHB).
Methods: Clinical data from 100 CHB patients admitted to our hospital from April 2022 to April 2024 were retrospectively reviewed. Of these, 45 cases in the control group received ETV, and 55 cases in the research group received TDF tablets.
Higher Relapse Rate in HBeAg-negative Patients After Cessation of Tenofovir Alafenamide Compared to Entecavir or Tenofovir Disoproxil Fumarate.
Am J Gastroenterol
January 2025
Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan.
Objectives: There is limited information comparing the off-therapy relapse rates of patients discontinued tenofovir alafenamide (TAF) to those stopping entecavir or tenofovir disoproxil fumarate (TDF).
Methods: A total of 805 HBeAg-negative patients without cirrhosis receiving entecavir (n=406), TDF (n=260) or TAF (n=139) were enrolled. Propensity-score (PS) matching method was applied to eliminate the significant differences in clinical characteristics.
Seroprevalence of specific antibodies to Treponema pallidum in blood donors with DNA confirmation of seropositivity.
Cell Mol Biol (Noisy-le-grand)
January 2025
Swedish Board Member of General Surgery, Kurdistan Higher Council of Medical Specialties, Erbil, Iraq.
The rising global incidence of syphilis underscores the risk of transmission through blood transfusions. Treponema pallidum, the pathogen responsible for syphilis, represents a major public health challenge. Accurate detection is essential for controlling the disease, particularly in asymptomatic blood donors.
View Article and Find Full Text PDFImmunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China.
Hum Vaccin Immunother
December 2025
Academy of Preventive Medicine, Shandong University, Jinan, China.
Acute hepatitis E infection could induce severe outcomes among chronic hepatitis B (CHB) patients. Between 2016 and 2017, an open-label study was conducted to evaluate the immunogenicity and safety of hepatitis E vaccine (HepE) in CHB patients, using healthy adults as parallel controls in China. Eligible participants who were aged ≥30 y were enrolled in the study.
View Article and Find Full Text PDFAll-positive HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb in a patient with hepatitis B: A case report.
Medicine (Baltimore)
January 2025
Department of Clinical Immunology, Nanjing Kingmed Clinical Laboratory, Nanjing, Jiangsu, China.
Rationale: Mass vaccination, low cost of immunoglobulins, and new drugs led to the emergence of new, unusual patterns of hepatitis B serum markers. This study reported a rare case of hepatitis B with all 5 positive serum markers, including HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb.
Patient Concerns: A 30-year-old female patient was admitted due to abnormal liver function.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!